Expression and role of the angiotensin II AT2 receptor in human prostate tissue: In search of a new therapeutic option for prostate cancer

• Published in: The Prostate Vol. 73; no. 10; pp. 1057 - 1068
• Main Authors: Guimond, Marie-Odile, Battista, Marie-Claude, Nikjouitavabi, Fatemeh, Carmel, Maude, Barres, Véronique, Doueik, Alexandre A., Fazli, Ladan, Gleave, Martin, Sabbagh, Robert, Gallo-Payet, Nicole
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2013; Wiley Subscription Services, Inc
• Subjects: angiotensin; Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; AT2 receptor; cancer; Cell Proliferation - drug effects; human prostate; Humans; Losartan - pharmacology; Losartan - therapeutic use; Male; primary cell culture; proliferation; Prostate - drug effects; Prostate - metabolism; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Receptor, Angiotensin, Type 2 - agonists; Receptor, Angiotensin, Type 2 - metabolism; Tissue Array Analysis; Tumor Suppressor Proteins - metabolism

BACKGROUND Evidence shows that angiotensin II type 1 receptor (AT1R) blockers may be associated with improved outcome in prostate cancer patients. It has been proposed that part of this effect could be due to angiotensin II type 2 receptor (AT2R) activation, the only active angiotensin II receptor i...